| Therapeutic class | Shortage rate |
|---|---|
| Agents acting on the renin-angiotensin system | 56% |
| Antacids, antiflatulents and anti-ulcerants | 51% |
| Topical corticosteroids | 49% |
| Calcium antagonists | 49% |
| Anti-parkinson drugs | 43% |
| Vaccines | 42% |
| Anti-acne preparations | 39% |
| Nasal preparations | 37% |
| Ophthalmologicals | 36% |
| Lipid-regulating/anti-atheroma preparations | 36% |
| All other classes | 23% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
September 2022
More information
Region
Canada
Survey time period
2019/2020
Supplementary notes
Therapeutic classes are defined based on the second level of the European Pharmaceutical Market Research Association (EphMRA) Anatomical Classification of Pharmaceutical Products. Therapeutic classes with fewer than 20 drugs with sales in Canada are excluded from the figure.
Citation formats
